Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Andrea Pirzkall"'
Autor:
Vinod Ganju, M. Karthaus, Alessio Amatu, Andrea Pirzkall, Amy V. Kapp, Michael Findlay, Maria Di Bartolomeo, Leslie Samuel, Manuel Hidalgo, Bruce McCall, Christopher Jackson, Roxana Ioana Sufan, Andrew L. Coveler, William D. Hanley, John Bridgewater, Matthew Burge, Elicia Penuel, Pilar García Alfonso, Andrew G. Hill, Josep Tabernero, Mark Jeffery
Publikováno v:
Clinical Cancer Research. 24:2276-2284
Purpose: Duligotuzumab is a dual-action antibody directed against EGFR and HER3. Experimental Design: Metastatic colorectal cancer (mCRC) patients with KRAS ex2 wild-type received duligotuzumab or cetuximab and FOLFIRI until progression or intolerabl
Autor:
Amy V. Kapp, Stephanie Royer-Joo, Lori J. Wirth, Antonio Jimeno, X. Wang, Tanguy Y. Seiwert, Jean-Pascal Machiels, Bruce McCall, Pol Specenier, Feby Mardjuadi, Elicia Penuel, Paul Clement, Andrea Pirzkall
Publikováno v:
Cancer. 122:3803-3811
BACKGROUND This open-label, multicenter, phase Ib study assessed the safety and preliminary activity of duligotuzumab, a dual-action antibody that blocks ligand binding to human epidermal growth factor receptor 3 (HER3) and epidermal growth factor re
Autor:
Omar Kabbarah, Thomas Sandmann, C Rumpel, Mark R. Lackner, Garret Hampton, Elicia Penuel, Richard Bourgon, Lukas C. Amler, Yulei Wang, Eloisa Fuentes, Christopher A. Moskaluk, Ling Fu, Josep Tabernero, Kwame Okrah, Andrea Pirzkall, Kimberly Walter, Shan Lu, Xueping Qu, Henry F. Frierson
Publikováno v:
Oncogene
Key molecular drivers that underlie transformation of colonic epithelium into colorectal adenocarcinoma (CRC) are well described. However, the mechanisms through which clinically targeted pathways are activated during CRC progression have yet to be e
Autor:
Mario R. Mautino, Ray S. Lin, John Edward Janik, Eugene P. Kennedy, Andrea Pirzkall, Charles J. Link, Xiaorong Liang, David H. Munn, Sami Mahrus, Bruce McCall, Nicholas N. Vahanian, Laurent Salphati, Zhonglin Hao, Stephanie Royer-Joo, Asha Nayak-Kapoor, Samir N. Khleif, Lisa Marshall, Ramses F. Sadek, W. Jay Ramsey, Kari M. Morrissey, Robin Dobbins
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-12 (2018)
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-12 (2018)
Background Indoleamine-2,3-dioxygenase 1 (IDO1) catalyzes the oxidation of tryptophan into kynurenine and is partially responsible for acquired immune tolerance associated with cancer. The IDO1 small molecule inhibitor navoximod (GDC-0919, NLG-919) i
Autor:
Maria Anderson, Danny Rischin, William D. Hanley, Jérôme Fayette, Andrea Pirzkall, Dana Cernea, Tibor Csoszi, Amy V. Kapp, Cristina Oprean, Christopher M. Nutting, Paul M. Harari, Lori J. Wirth, Bruce McCall, Paul H. O'Brien, Anghel Udrea, Elicia Penuel, Jan B. Vermorken, Antonio Jimeno
Publikováno v:
Frontiers in Oncology
Frontiers in oncology
Frontiers in Oncology, Vol 6 (2016)
Frontiers in oncology
Frontiers in Oncology, Vol 6 (2016)
Background: Duligotuzumab, a novel dual -action humanized IgG1 antibody that blocks ligand binding to epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3), inhibits signaling from all ligand-dependent HER dimers
Autor:
Manuel Hidalgo, Anne Uyei, J. Paul Eder, Jordan Berlin, Andrea Pirzkall, S. Gail Eckhardt, Bruce McCall, Patricia LoRusso, Amy Lew Tsuhako, Christopher H. Lieu, Amy V. Kapp, Josep Tabernero, Andrew H. Ko, David E. Gerber, Andrés Cervantes
Publikováno v:
The Oncologist
Lessons Learned Cobimetinib and duligotuzumab were well tolerated as single agents and in combination with other agents. The cobimetinib and duligotuzumab combination was associated with increased toxicity, most notably gastrointestinal, and limited
Autor:
Danijela Jelovac, Joseph Paul Eder, Christopher H. Lieu, Andrea Pirzkall, Roland Morley, F. Stephen Hodi, Howard A. Burris, Frank Tsai, Sami Mahrus, Amy Lew Tsuhako, Michael S. Gordon, Kari M. Morrissey, Leisha A. Emens, Jeffrey R. Infante, James M. Cleary, Sarah Lindsey Davis, Ray S. Lin, Lars Mueller, Matthew D. Hellmann, Patricia LoRusso
Publikováno v:
Journal of Clinical Oncology. 35:105-105
105 Background: GDC-0919, a small molecule inhibitor of indoleamine-2,3-dioxygenase 1 (IDO1), reduces tryptophan catabolism and kynurenine production within the tumor microenvironment that may promote normal effector T cell activity and an immunogeni